Darren Mylotte1*, BCh, MD; Nicolo Piazza2, MD, PhD; Patrick W. Serruys3, MD, PhD
1. Galway University Hospital, Galway, Ireland; 2. McGill Healthcare Centre, Montreal, Quebec, Canada; 3. International Centre of Circulatory Health, Imperial College London, London, United Kingdom
“I am a slow walker, but I never walk back.”
Since Professor Alain Cribier first performed a transcatheter aortic valve implantation (TAVI) in June 20021, TAVI has emerged as a safe, effective, and widely practised intervention that has transformed the lives of hundreds of thousands of patients worldwide2 and has answered an unmet clinical need as TAVI is now the standard of care for inoperable patients and the preferred therapeutic option for high-risk patients with severe aortic stenosis3,4. Moreover, transcatheter heart valve (THV) technology has expanded well beyond Professor Cribier’s initial intentions, and is frequently ...